J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stambaugh, J.
Right arrow Articles by Davis, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stambaugh, J.
Right arrow Articles by Davis, M
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients

JE Stambaugh, RF Reder, MD Stambaugh, H Stambaugh, and M Davis

Thirty patients with cancer pain completed a double-blind crossover study comparing controlled-release (CR) and immediate-release (IR) oxycodone. In open-label titration (2 to 21 days), these patients were stabilized on IR oxycodone qid. They were then randomized to double-blind treatment with CR oxycodone q12h or IR oxycodone qid for 3 to 7 days followed by crossover at the same daily dose. Mean (+/- SD) pain intensity (0 = none to 10 = severe) decreased from a baseline of 6.0 +/- 2.2 to 2.7 +/- 1.1 after titration with IR oxycodone dosed qid. Pain intensity remained stable throughout double-blind treatment: 2.7 +/- 1.9 with CR oxycodone and 2.8 +/- 1.9 with IR oxycodone. Acceptability of therapy and pain scores correlated with plasma oxycodone concentrations for each interval and were similar for both medications (IR and CR oxycodone). Adverse events were similar for both formulations. Following repeat dosing under double-blind conditions, oral CR oxycodone administered q12h provided analgesia comparable to IR oxycodone given qid.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
C. E. Argoff and D. I. Silvershein
A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs
Mayo Clin. Proc., July 1, 2009; 84(7): 602 - 612.
[Abstract] [Full Text] [PDF]

Home page
 AJPHHome page
A. Van Zee
The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy
Am J Public Health, February 1, 2009; 99(2): 221 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
M. D. Hix
Pain Management in Elderly Patients
Journal of Pharmacy Practice, February 1, 2007; 20(1): 49 - 63.
[Abstract] [PDF]

Home page
 J Am Board Fam MedHome page
R. Sinatra
Opioid Analgesics in Primary Care: Challenges and New Advances in the Management of Noncancer Pain
J Am Board Fam Med, March 1, 2006; 19(2): 165 - 177.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Clinical Pharmacology